Published in Retina

When Testosterone Use Triggers Central Serous Chorioretinopathy

This is editorially independent content supported by advertising from Apellis Pharmaceuticals
11 min read

Join Jay Haynie, OD, FAAO, FORS, and Daniel Epshtein, OD, FAAO, to review a case report of central serous chorioretinopathy (CSC) caused by testosterone use.

On this episode of Ready, Set, Retina, Daniel Epshtein, OD, FAAO, is joined by Jay M. Haynie, OD, FAAO, FORS, to review a case report of central serous chorioretinopathy (CSCR) secondary to testosterone use.
Dr. Haynie practices at Sound Retina in Tacoma, Washington, and is an adjunct assistant clinical professor at the Pacific University College of Optometry.

Overview of central serous chorioretinopathy

CSCR is a retinal disorder characterized by localized serous retinal detachment of the macula secondary to retinal pigment epithelium (RPE) decompensation and choroidal vascular changes.1 While most acute cases resolve spontaneously and patients regain normal vision, in chronic cases, intervention is required to prevent permanent vision loss.
Recurrence happens in around 31% of CSCR patients, although the rate has been identified as being as high as 50% in some studies.2 Typically, CSCR occurs in males aged 20 to 45 years, and patients tend to complain of central vision loss or distortion.2
Of note, CSCR is the fourth most common retinopathy after age-related macular degeneration, diabetic retinopathy, and branch retinal vein occlusion.3

Central serous chorioretinopathy case report

Case presentation

A 38-year-old white male patient was referred to the clinic with a 1-month history of central distortion and blurred vision in the left eye. He reported that this was the first episode of visual symptoms in his life. The patient’s medical history was remarkable for anxiety and low serum testosterone, for which he was being treated with bupropion and weekly testosterone injections.
The patient’s best-corrected visual acuity (BCVA) was 20/20 in the right eye (OD) and 20/20- in the left eye (OS). Dr. Haynie explained that based on his clinical experience treating CSCR patients, their Snellen acuity is often quite good, but patients tend to fear that they are going blind due to their visual symptoms, including metamorphopsia.

Retinal imaging at baseline

Figure 1: Color fundus photography (CFP) captured at the initial visit; a localized serous retinal detachment and sheen from the internal limiting membrane can be visualized; there is no evidence of hemorrhage, lipid, or pigmentary changes, and the retinal vasculature appears healthy.
CFP Baseline
Figure 1: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 2: Optical coherence tomography (OCT) imaging OS taken at the initial visit; an area of subretinal fluid defining the focal neurosensory retinal detachment can be seen;4 additionally, the choroid appears thickened, which by definition places CSCR on the pachychoroid spectrum.1 Dr. Haynie emphasized the importance of paying attention to choroidal thickness in retinal imaging, as it has been implicated in various retinal and choroidal diseases.5
OCT Baseline
Figure 2: Courtesy of Jay M. Haynie, OD, FAAO, FORS.

Management of CSCR

Based on the findings from the retinal imaging, Dr. Haynie diagnosed the patient with CSCR, and he reviewed several of the common risk factors for CSCR, such as:1
  • Exposure to corticosteroids
  • Unaddressed stress or anxiety disorders in chronic cases
  • Testosterone usage
  • Sleep apnea in recurrent cases (61% incidence)6
  • High caffeine consumption
He added that while patients are likely anxious about the visual symptoms, CSCR is often a self-limiting disease, and most patients recover vision over the course of 2 to 3 months.7
In chronic cases, or for patients who seek faster resolution of visual symptoms, CSCR therapies may include:2
  • Topical dorzolamide 2% BID
  • Oral acetazolamide 250mg PO qhs
  • Eplerenone 50mg PO qAM
  • Rifampicin 300/600mg daily
  • Argon laser photocoagulation
  • Photodynamic therapy
  • Anti-vascular endothelial growth factor (VEGF)
Dr. Haynie remarked that he usually starts CSCR patients on acetazolamide, topical dorzolamide, or eplerenone (which is a medication similar to spironolactone). He added that rifampicin, an antimicrobial tuberculosis drug, has gained some momentum as an alternative treatment due to its effect on serum cortisol and low cost.8
For patients who do not respond to medical management, focal laser photocoagulation (if the lesion is extrafoveal) and half-fluence photodynamic therapy can work well to resolve the fluid accumulation, noted Dr. Haynie.9 He opts to reserve anti-VEGF injections for patients with secondary choroidal neovascular membranes (CNVMs), which can occur in patients with chronic CSCR.10
Dr. Haynie discussed with the patient how the testosterone injections may be connected to his visual symptoms. He added that, anecdotally, he has found that many patients with low testosterone prefer not to reduce their dosage—which was also true for this patient.
As such, the patient elected to pursue treatment, and Dr. Haynie subsequently prescribed 50mg of oral eplerenone daily. Since the patient reported an allergy to sulfa drugs, dorzolamide and acetazolamide were excluded as potential options.

1- and 3-month follow-up visits

At the 1-month follow-up visit, the neurosensory retinal detachment and subretinal fluid had fully resolved. Unfortunately, 2 months later, the patient returned with a second episode of CSCR. Knowing that he had responded well to eplerenone, Dr. Haynie prescribed a second course of the treatment, and the patient again responded well.

6-month follow-up visit

However, 6 months later, the patient returned with a third recurrence of CSCR, which suggested that the etiology was likely linked to his testosterone usage. To round out his comprehensive workup, Dr. Haynie referred the patient to a sleep specialist due to the relatively high incidence of recurrent CSCR (61%) in patients with sleep apnea.6
During this visit, Dr. Haynie ordered fluorescein and indocyanine green (ICG) angiography, which is not something he often does for patients with acute CSCR; however, for recurrent cases, he noted that it is important to identify where the focal leak is in the choroid and rule out CNVMs.
Figure 3: Fluorescein angiography imaging OS during the third recurrence of CSCR; a focal lesion just outside of the central macula can be seen.
Fluorescein Angiography 6-month
Figure 3: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 4: ICG angiography imaging OS during the third recurrence of CSCR; a focal extrafoveal leakage in the central macula can be visualized, there is no presence of choroidal neovascularization, but there is hypercyanesence, which is leaking in the choroid.
ICG Angiography 6 months
Figure 4: Courtesy of Jay M. Haynie, OD, FAAO, FORS.

Post-laser photocoagulation

The patient was subsequently referred for laser photocoagulation treatment, after which he remained stable with no additional recurrences over the next several years.
Figure 5: Near-infrared reflectance (NIR) imaging OS after laser photocoagulation; the yellow circle highlights where the laser treatment was performed, and mottling of the pigment can be visualized beneath the treated tissue.
NIR Post-Laser
Figure 5: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 6: OCT imaging OS after laser photocoagulation; the neurosensory detachment is resolved, although there has been a slight alteration to the outer retinal/RPE complex due to the chronic presence of subretinal fluid.
OCT Post-Laser
Figure 6: Courtesy of Jay M. Haynie, OD, FAAO, FORS.

Comparing retinal imaging of acute and chronic CSCR

Dr. Haynie then compared CFP, fundus autofluorescence (FAF), and OCT imaging from patients with acute and chronic CSCR. He explained that even if it is his first interaction with a CSCR patient, he orders FAF imaging because it is helpful in differentiating between acute and chronic CSCR.11
Figure 7: CFP and FAF imaging OD in a patient with acute CSCR; serous elevation can be visualized in CFP, and relative foveal hyperautofluorescence is noted with FAF.
CFP and FAF Acute CSC
Figure 7: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 8: OCT imaging OD in a patient with acute CSCR; the photoreceptor layer is smooth and subretinal fluid can be visualized.
OCT Acute CSC
Figure 8: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 9: FAF imaging OS of a patient with chronic CSCR; serous-related RPE alteration can be visualized in the superior and inferior temporal arcades and scattered throughout the macula; in addition, there are drip lines of hyperautofluorescence, which indicates that subretinal fluid has tracked underneath the retina. Dr. Haynie noted that this patient likely had CSCR for decades.
FAF Chronic CSC
Figure 9: Courtesy of Jay M. Haynie, OD, FAAO, FORS.
Figure 10: OCT imaging OD of a patient with chronic CSCR; accumulation of RPE outer segment shedding (known as “shaggy” photoreceptors) can be visualized.12 OCT is another important tool for identifying and monitoring CSCR patients and differentiating chronic from acute cases.12
OCT Chronic CSC
Figure 10: Courtesy of Jay M. Haynie, OD, FAAO, FORS.

Conclusion

When treating a patient who presents with CSCR, optometrists can:
  1. Use CFP, FAF, and OCT to assess the extent of fluid accumulation and chronicity of the disease, as well as determine if there is choroidal neovascularization.
  2. Identify and address risk factors by educating patients on how they can limit associated factors that may cause CSCR.
    1. Make sure to ask CSCR patients if they have been diagnosed with sleep apnea, or if they seem to have any symptoms associated with the disease.
  3. If the case is mild, patients can be followed regularly to monitor resolution.
    1. Use fluorescein or ICG angiography to identify choroidal leakage and guide the treatment protocol moving forward.
  4. If the patient has recurrent CSCR, initiating treatment is recommended to preserve the quality of the photoreceptor outer segments and prevent potential vision loss.
    1. Monitor patients for choroidal neovascularization.
  1. Gupta A, Tripathy K. Central Serous Chorioretinopathy. In: StatPearls. Treasure Island (FL):StatPearls Publishing; August 23, 2023. Accessed September 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK558973/.
  2. Mi CW, Lee DW, Sun J, et al. Central Serous Chorioretinopathy. EyeWiki. June 6, 2024. Accessed September 11, 2024. https://eyewiki.org/Central_Serous_Chorioretinopathy.
  3. Wang M, Munch IC, Hasler PW, et al. Central Serous Chorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145. doi: 10.1111/j.1600-0420.2007.00889.x
  4. Pitcher JD III, Hsu J. CSCR: Diagnosis and Treatment. Review of Ophthalmology. July 7, 2014. Accessed September 11, 2024. https://www.reviewofophthalmology.com/article/cscr-diagnosis-and-treatment.
  5. Xie R, Qiu B, Zhang X. Evaluation of Choroidal Thickness Using Optical Coherence Tomography: A Review. Front Med (Lausanne). 2021;8:783519. doi: 10.3389/fmed.2021.783519
  6. Yavaş GF, Kübesci T, Kaşikci M, et al. Obstructive Sleep Apnea in Patients with Central Serous Chorioretinopathy. Curr Eye Res. 2014;39(1):88-92. Doi: 10.3109/02713683.2013.824986
  7. Liew G, Quin G, Fraser-Bell S. Central Serous Chorioretinopathy: A Review of Epidemiology and Pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201-214. doi: 10.1111/j.1442-9071.2012.02848.x
  8. Venkatesh R, Agarwal M, Kantha M. Efficacy of Oral Rifampicin in Chronic Central Serous Chorioretinopathy. Ther Adv Ophthalmol. 2018;10:2515841418807130. doi: 10.1177/2515841418807130
  9. Parodi MB, Arrigo A, Iacono P, et al. Central Serous Chorioretinopathy: Treatment with Laser. Pharmaceuticals (Basil). 2020;13(11):359. doi: 10.3390/ph13110359
  10. Palakkamanil M, Munro M, Sethi A, Adatia F. Intravitreal Anti-Vascular Endothelial Growth Factor for the Teratment of Chronic Central Serous Retinopathy: A Meta-Analysis of the Literature. BMJ Open Ophthalmol. 2023;8(1):e001310. doi: 10.1136/bmjophth-2023-001310
  11. Lee WJ, Lee JH, Lee BR. Fundus Autofluorescence Imaging Patterns in Central Serous Chorioretinopathy According to Chronicity. Eye (Lond). 2016;30(10):1336-1342. Doi: 10.1038/eye.2016.113
  12. Rafieetary M, Haynes J, Attar R. Get Serious About Central Serous Chorioretinopathy. Review of Optometry. June 15, 2021. Accessed September 11, 2024. https://www.reviewofoptometry.com/article/get-serious-about-central-serous-chorioretinopathy.
Jay M Haynie, OD, FAAO, FORS
About Jay M Haynie, OD, FAAO, FORS

Jay M. Haynie, OD, FAAO, FORS, graduated from Pacific University College of Optometry in 1992 and completed a residency at American Lake Veterans Hospital in 1993, where the focus was on the diagnosis and management of ocular disease. Dr. Haynie served as the Executive Clinical Director of Retina and Macula Specialists until 2018, after which time he joined Sound Retina in Tacoma, Washington.

He is an adjunct clinical professor at Pacific University College of Optometry, a Fellow of the American Academy of Optometry, and a member of the Optometric Retina Society. Dr. Haynie is a sponsor of a 4th year internship for Optometry students in his private practice.

He is a clinical investigator and continues to be involved in clinical studies regarding retinal disease management, both as a principal and sub-investigator. He is a published author and has become a nationally recognized speaker on advances in technology and the management of retinal disease.

Jay M Haynie, OD, FAAO, FORS
Daniel Epshtein, OD, FAAO
About Daniel Epshtein, OD, FAAO

Dr. Daniel Epshtein is an assistant professor and the coordinator of optometry services at the Mount Sinai Morningside Hospital ophthalmology department in New York City. Previously, he held a position in a high-volume, multispecialty practice where he supervised fourth year optometry students as an adjunct assistant clinical professor of the SUNY College of Optometry. Dr. Epshtein’s research focuses on using the latest ophthalmic imaging technologies to elucidate ocular disease processes and to help simplify equivocal clinical diagnoses. He lectures on multiple topics including multimodal imaging, glaucoma, retina, ocular surface disease, and perioperative care.

Daniel Epshtein, OD, FAAO
How would you rate the quality of this content?
Eyes On Eyecare Site Sponsors
Astellas LogoOptilight by Lumenis Logo